SAN FRANCISCO, CA / ACCESSWIRE / October 16, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Jaguar family company Napo Pharmaceuticals ("Napo") has initiated the commercial ...

We are thrilled to have begun our commercial launch of Gelclair. Oral mucositis is undertreated and underappreciated. We believe we can help cancer patients by giving them a supportive care ...

Jaguar Health, Inc. announced that Jaguar family company Napo Pharmaceuticals (Napo) has initiated the commercial launch of the FDA-approved oral mucositis prescription product Gelclair in the US.

Oropharyngeal mucositis is an acute and distressing toxic effect of chemotherapy and head and neck irradiation. This oral sequela significantly impairs the daily functioning and quality of life of ...

Shares of Sutro Biopharma (NASDAQ:STRO) fell by 17% in September after the company's ESMO (European Society ... is misrepresented in my eyes, as NCCN guidelines recommend its use with Avastin ...

T he stock of small-cap biotech Jaguar Health Inc. rose 7% on Wednesday, after the company launched its gelclair treatment for oral mucositis, a common side effect suffered by head and neck cancer ...

The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD-1 inhibitor Jemperli (dostarlimab) – achieved a higher objective ...

Please purchase a Premium Subscription to continue reading. To continue, please log in, or sign up for a new account. We offer one free story view per month. If you ...

The data was still under wraps at that time, but has just been revealed in the ESMO congress abstract drop – a 3.2 month improvement over control, compared to 1.6 months at ASCO. Taken in ...